Armed with patient genetic information, clinicians can more quickly identify effective therapies, thus limiting the prolonged suffering and economic burden placed upon many patients with chronic illnesses. Several examples are available which demonstrate the utility and effectiveness of testing in practice for a variety of clinical diagnoses. This is demonstrated in the following published patient cases. One case describes an 18-year-old male diagnosed with intermittent explosive disorder, suffering from uncontrolled anger outbursts and several failed medication trials, who elected to utilize genetic testing. The results guided his clinician to initiate lithium, which markedly reduced his symptoms, with no adverse medication effects, and allowed him to improve his school work, social, and family life. Lithium was chosen as an intervention for this patient as he had variations in the SLC6A4, DRD2, and 5HT2C, increasing his risk for failure and intolerance with SSRIs and antipsychotic agents. Thus, a treatment strategy which did not target the serotonin transporter or dopamine receptor pathway would likely be better tolerated in this patient. In another patient case, a clinician treating a 31-year-old female suffering from severe depressive symptoms was able to utilize genetic testing, and the resulting therapeutic choices led to complete remission of the patient's symptoms. In this example, lamotrigine was chosen in response to clinical presentation, as well as a variation in the ANK3 gene. ANK3 is a protein related to sodium channels and is involved in neuronal excitability. Lamotrigine was utilized to stabilize the patient's mood and for its potential as a modulator of sodium channel activity.